Design Therapeutics Net Worth
Design Therapeutics Net Worth Breakdown | DSGN |
Design Therapeutics Net Worth Analysis
Design Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Design Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Design Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Design Therapeutics' net worth analysis. One common approach is to calculate Design Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Design Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Design Therapeutics' net worth. This approach calculates the present value of Design Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Design Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Design Therapeutics' net worth. This involves comparing Design Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Design Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Design Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Design Therapeutics' net worth research are outlined below:
| Design Therapeutics is way too risky over 90 days horizon | |
| Design Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (49.59 M) with loss before overhead, payroll, taxes, and interest of (44.53 M). | |
| Design Therapeutics currently holds about 359.38 M in cash with (43.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Should you wait for a breakout in Design Therapeutics Inc. - Market Risk Summary Weekly Momentum Stock Picks - newser.com |
Design Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Design Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Design Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Design Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Design Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Design Therapeutics backward and forwards among themselves. Design Therapeutics' institutional investor refers to the entity that pools money to purchase Design Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2025-06-30 | 840.8 K | Geode Capital Management, Llc | 2025-06-30 | 794 K | Woodline Partners Lp | 2025-06-30 | 777.5 K | State Street Corp | 2025-06-30 | 719.2 K | Mpm Oncology Impact Management Lp | 2025-06-30 | 555.2 K | D. E. Shaw & Co Lp | 2025-06-30 | 390.6 K | Northern Trust Corp | 2025-06-30 | 362.5 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 313.4 K | Renaissance Technologies Corp | 2025-06-30 | 267.8 K | Sr One Capital Management, Lp | 2025-06-30 | 6.5 M | Logos Global Management Lp | 2025-06-30 | 4.2 M |
Follow Design Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 332.01 M.Market Cap |
|
Project Design Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.26) | (0.24) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.20) | (0.19) |
When accessing Design Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Design Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Design Therapeutics' profitability and make more informed investment decisions.
Evaluate Design Therapeutics' management efficiency
Design Therapeutics has return on total asset (ROA) of (0.1902) % which means that it has lost $0.1902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2677) %, meaning that it created substantial loss on money invested by shareholders. Design Therapeutics' management efficiency ratios could be used to measure how well Design Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of October 2025, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to grow to -0.24. As of the 21st of October 2025, Asset Turnover is likely to grow to 0.000007, while Total Assets are likely to drop about 240.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.28 | 3.05 | |
| Tangible Book Value Per Share | 4.28 | 3.05 | |
| Enterprise Value Over EBITDA | (6.71) | (7.05) | |
| Price Book Value Ratio | 1.44 | 1.51 | |
| Enterprise Value Multiple | (6.71) | (7.05) | |
| Price Fair Value | 1.44 | 1.51 | |
| Enterprise Value | 328.9 M | 369.6 M |
At Design Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Design Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Design Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Design Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Design Therapeutics Corporate Filings
8K | 10th of September 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 28th of August 2025 Other Reports | ViewVerify | |
F4 | 14th of August 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 23rd of May 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Design Therapeutics Earnings per Share Projection vs Actual
Design Therapeutics Corporate Management
| Jim Kerr | Chief Development | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Doane Chilcoat | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Mustapha Parekh | General Counsel | Profile | |
| MD FACC | Consulting Officer | Profile | |
| Dawn Giangiulio | Controller | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.